*nlm.life
			PubMed Journals: Drug Discov Today

  Source:		PMID: 32006468


    		Drug Discov Today. 2020 Jan 30. pii:
     		S1359-6446(20)30041-6. doi:
			10.1016/j.drudis.2020.01.015. [Epub ahead of
			print]

			Recent discovery and development of inhibitors
			targeting coronaviruses.

			Pillaiyar T(1), Meenakshisundaram S(2),
			Manickam M(3).

			Author Information
			(1) PharmaCenter Bonn, Pharmaceutical
			Institute, Department of Pharmaceutical and
			Medicinal Chemistry, University of Bonn, An der
			Immenburg 4, D-53121 Bonn, Germany.
			Electronic address: thanigai@uni-bonn.deand.
			(2) Department of Chemistry, Sri Krishna
			College of Engineering and Technology,
			Coimbatore, Tamil Nadu, India.
			(3) Department of Chemistry, PSG Institute of
			Technology and Applied Research,
			Coimbatore, Tamil Nadu, India. Electronic
			address: manojm@psgitech.ac.in.

			Human coronaviruses (CoVs) are enveloped
			viruses with a positive-sense single-stranded
			RNA genome. Currently, six human CoVs have
			been reported including human coronavirus
			229E (HCoV-229E), OC43 (HCoV-OC43), NL63
			(HCoV-NL63), HKU1 (HCoV-HKU1),
			severe acute respiratory syndrome (SARS)
			coronavirus (SARS-CoV), and MiddleEast
			respiratory syndrome (MERS) coronavirus
			(MERS-CoV). They cause moderate to severe
			respiratory and intestinal infections in humans.
			In this review, we focus on recent advances in
			the research and development of
			small-molecule anti-human coronavirus
			therapies targeting different stages of the CoV
			life cycle.

			Copyright © 2020 Elsevier Ltd. All rights
			reserved.

			DOI: 10.1016/j.drudis.2020.01.015
			PMID: 32006468

     			                         Tweet       Print